GB9708092D0 - Materials and methods relating to inhibiting the interaction of p53 and mdm2 - Google Patents
Materials and methods relating to inhibiting the interaction of p53 and mdm2Info
- Publication number
- GB9708092D0 GB9708092D0 GBGB9708092.3A GB9708092A GB9708092D0 GB 9708092 D0 GB9708092 D0 GB 9708092D0 GB 9708092 A GB9708092 A GB 9708092A GB 9708092 D0 GB9708092 D0 GB 9708092D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- mdm2
- cells
- inhibiting
- interaction
- materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Optical Record Carriers And Manufacture Thereof (AREA)
- Paper (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Abstract
Mdm2 binds to p53 in cells in which mdm2 is not overexpressed, i.e. in cells in which mdm2 is expressed at normal or low levels, and that in these cells, this interaction targets the p53 for degradation. This finding means that inhibiting mdm2 production and/or inhibiting the binding of mdm2 to p53 allows levels of p53 to increase by reducing the clearance of p53 by mdm2, and can be used to activate p53 function in cells other than those in which mdm2 is overexpressed. This allows the use of an agent having the property of disrupting the binding of p53 and mdm2 or inhibiting the production of mdm2 in a population of cells, in the preparation of a medicament for activating p53, wherein the population of cells do not overexpress mdm2. Such medicaments are useful in the treatment of conditions such as cancer, viral infections or conditions in which p53 or mdm2 is not functional.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9708092.3A GB9708092D0 (en) | 1997-04-22 | 1997-04-22 | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
CA002287344A CA2287344A1 (en) | 1997-04-22 | 1998-04-20 | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
PCT/GB1998/001144 WO1998047525A1 (en) | 1997-04-22 | 1998-04-20 | MATERIALS AND METHODS RELATING TO INHIBITING THE INTERACTION OF p53 AND mdm2 |
AU70644/98A AU731431B2 (en) | 1997-04-22 | 1998-04-20 | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
DE69813204T DE69813204T2 (en) | 1997-04-22 | 1998-04-20 | MATERIALS AND METHODS RELATED TO INHIBITING THE INTERACTION OF THE P53 AND MDM2 |
EP98917411A EP0977580B1 (en) | 1997-04-22 | 1998-04-20 | MATERIALS AND METHODS RELATING TO INHIBITING THE INTERACTION OF p53 AND mdm2 |
AT98917411T ATE236651T1 (en) | 1997-04-22 | 1998-04-20 | MATERIALS AND METHODS RELATED TO INHIBITING THE INTERACTION OF P53 AND MDM2 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9708092.3A GB9708092D0 (en) | 1997-04-22 | 1997-04-22 | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB9708092D0 true GB9708092D0 (en) | 1997-06-11 |
Family
ID=10811137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9708092.3A Pending GB9708092D0 (en) | 1997-04-22 | 1997-04-22 | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0977580B1 (en) |
AT (1) | ATE236651T1 (en) |
AU (1) | AU731431B2 (en) |
CA (1) | CA2287344A1 (en) |
DE (1) | DE69813204T2 (en) |
GB (1) | GB9708092D0 (en) |
WO (1) | WO1998047525A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
CA2682174C (en) | 2007-03-28 | 2021-04-06 | President And Fellows Of Harvard College | Stitched polypeptides |
WO2012021876A2 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CN108929375A (en) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | Peptidomimetic macrocyclic compound |
TWI583792B (en) * | 2011-11-09 | 2017-05-21 | 曼茲法瑪股份有限公司 | Neurotoxins exhibiting shortened biological activity |
ES2817877T3 (en) | 2012-02-15 | 2021-04-08 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
JP6526563B2 (en) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | Disubstituted amino acids and methods for their preparation and use |
BR112017005736A2 (en) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | peptidomimetic macrocycles and formulations thereof |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
CN108368161A (en) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | Peptidomimetic macrocyclic compound as MCL-1 conditioning agents |
US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
US5770377A (en) * | 1994-07-20 | 1998-06-23 | University Of Dundee | Interruption of binding of MDM2 and P53 protein and therapeutic application thereof |
DE69738754D1 (en) * | 1996-07-05 | 2008-07-17 | Cancer Rec Tech Ltd | HEMMER OF INTERACTION BETWEEN P53 AND MDM2 |
-
1997
- 1997-04-22 GB GBGB9708092.3A patent/GB9708092D0/en active Pending
-
1998
- 1998-04-20 WO PCT/GB1998/001144 patent/WO1998047525A1/en active IP Right Grant
- 1998-04-20 AT AT98917411T patent/ATE236651T1/en active
- 1998-04-20 CA CA002287344A patent/CA2287344A1/en not_active Abandoned
- 1998-04-20 AU AU70644/98A patent/AU731431B2/en not_active Ceased
- 1998-04-20 DE DE69813204T patent/DE69813204T2/en not_active Expired - Fee Related
- 1998-04-20 EP EP98917411A patent/EP0977580B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0977580A1 (en) | 2000-02-09 |
EP0977580B1 (en) | 2003-04-09 |
AU7064498A (en) | 1998-11-13 |
ATE236651T1 (en) | 2003-04-15 |
WO1998047525A1 (en) | 1998-10-29 |
DE69813204D1 (en) | 2003-05-15 |
AU731431B2 (en) | 2001-03-29 |
DE69813204T2 (en) | 2004-02-05 |
CA2287344A1 (en) | 1998-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9708092D0 (en) | Materials and methods relating to inhibiting the interaction of p53 and mdm2 | |
AU2003274071A1 (en) | Dosage form that is safeguarded from abuse | |
NO974694L (en) | Pharmaceutical preparation containing N-phosphonoglycine derivatives to inhibit cancer and virus growth | |
BR9811121A (en) | Product, pharmaceutical composition, and use of a product | |
TR200100824T2 (en) | Benzothiepines with activity as inhibitors of bile acid transport and taurocholate uptake in ileum | |
AU3847997A (en) | Inhibitors of the interaction between P53 and MDM2 | |
ATE243501T1 (en) | CONTROLLED RELEASE PREPARATION | |
DK0778731T3 (en) | Ion polymers containing biologically active anions | |
BR9814698A (en) | Combination of an aldose reductase inhibitor with a glycogen phosphorylase inhibitor | |
BRPI0411319A (en) | therapeutically active compounds and their use | |
AU6783698A (en) | Polyaromatic antiviral compositions | |
BR0012677A (en) | Enzyme-catalyzed therapeutic activation | |
BR9610386A (en) | Use of a compound capable of antagonizing, at least partially, the oncogenic activity of the mdm2 protein, use of an scfv, directed against the 1-134 domain of the mdm2 protein, use of a nucleic acid encoded for a compound capable of antagonizing the oncogenic activity mdm2 protein, viral vector and pharmaceutical composition | |
EP0696456A3 (en) | Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases | |
CA2388939A1 (en) | Therapeutic treatments for blood cell deficiencies | |
NO974693L (en) | Pharmaceutical preparation containing N-chlorophenylcarbamates, N-chlorophenylthiocarbamates and N-phosphonoglycine derivatives to inhibit mammalian cancer and virus growth | |
AR003176A1 (en) | A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER | |
NO974696L (en) | Pharmaceutical preparation containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibition of virus and cancer growth | |
AU8239298A (en) | Nucleotide-comprising composition | |
AU3052799A (en) | Pharmaceutical compositions comprising erythropoietin for treatment of cancer | |
WO2001041747A3 (en) | Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer | |
BR0004367A (en) | Pellet and manufacturing process. | |
IL114382A (en) | Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament | |
AU5158000A (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
AU1469097A (en) | Pharmaceutical compounds |